Naltrexone XR: When & How to Initiate?
Naltrexone XR is an opioid antagonist, which is FDA approved for opioid use disorder. The main benefits of naltrexone-XR are:
- extended duration of its action protecting individuals from relapse for a month
- avoiding non-adherence risk of daily medication compliance.
- improved treatment retention.
- effectiveness of XR-naltrexone is comparable to buprenorphine.
NALTREXONE XR: WHEN & HOW TO INITIATE?
Let’s begin by answering this question first:
Time's up
WATCH THE FOLLOWING 5 MIN VIDEO DISCUSSION TO FIND YOUR ANSWER:
INTERESTED IN LEARNING MORE?
Watch the following academy chapter summarizing this clinically relevant topic in the following five sections:
WATCH ACADEMY CHAPTER:
This chapter will be discussed in the following sections:Â
- Assessment: before initiation of Naltrexone XR
- Clinical Opiate Withdrawal Scale (COWS)
- Naltrexone (oral) challenge test
- Naloxone (i.m) challenge test
- When NOT to prescribe Naltrexone XR: Contraindications.
References:
- Am J Drug Alcohol Abuse. 2020 May 3; 46(3): 289–296.
- Lancet. 2011 Apr 30; 377(9776):1506-13.
- JAMA Psychiatry. 2017 Dec 1; 74(12):1197-1205.
INTERESTED IN LEARNING MORE?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.Â
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.Â
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Conference Discounts: Academy members get discounted access at our conferences.Â
- Goal: is to have all important clinically relevant topics in one place for ease of access.
Â
SUBSCRIBE TO OUR EMAIL NEWSLETTER: